With our partner in Europe, PLC continues to provide Regulatory support for the development of ARS-1. ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for NeffyTM (ARS-1; epinephrine nasal spray) Agreement will give access to millions at risk for severe allergic reaction to new pain-free delivery method for
PLC supports the Regulatory filings and clinical trials (set-up, site management, data management, etc) and received Fast Track Designation for ARS-1. ARS Pharmaceuticals Announces New Patent on ARS-1 (epinephrine nasal spray) Patent approval covers fast-acting decreased dosage level for intranasal administration for type 1 allergic reaction. SAN DIEGO (July 13, 2020) – ARS Pharmaceuticals today
PLC continues to support the Regulatory filings and the Clinical Trial operations for ARS Pharmaceuticals as they successfully advance the development of ARS-1. ARS Pharmaceuticals Announces Results from EPI-04 Clinical Study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis Results demonstrate rapid epinephrine absorption with an overall pharmacokinetic profile comparable to epinephrine
PLC’s continued Regulatory support of Intravail® and its technology has assisted in the advancement of ARS-1 and its product development. Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals’ Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure to Epinephrine Injectors / 4 May 2020 / 0 Comments — ARS Pharmaceuticals’ lead product, ARS-1 (epinephrine nasal spray) to treat severe allergic reactions, has
PLC’s continued support of Neurelis in regulatory filings and clinical trial development, site management, data management for multiple successful trials and new product development results in approval and commercial availability of Valtoco®. Neurelis Announces Commercial Availability- Valtoco® (Diazepam Nasal Spray) for Seizure Cluster Rescue — VALTOCO is the first and only nasal spray treatment for